Overview
Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics and Beyond is a one-day educational conference jointly sponsored by the Fred Hutch Cancer Center and Physicians’ Education Resource (PER®).
This program will focus on the practical integration of next-generation immune-based therapies in select hematologic and solid tumors, examining how rapidly evolving treatment modalities are reshaping clinical care. Expert faculty will address the current and emerging roles of cellular therapies, antibody drug conjugates (ADCs), bispecific antibodies, and novel immune approaches, with an emphasis on real-world application. A dedicated focus will be placed on helping community oncology teams strengthen the infrastructure and workflows needed to operationalize bispecific antibodies, including patient identification, step up dosing logistics, standardized monitoring, toxicity triage, and escalation pathways.
Clinical discussions will center on the role of immune therapies in the management of:
- Breast Cancer
- Genitourinary Cancers
- Lymphoma
- Melanoma
- Multiple Myeloma
The agenda will feature interactive discussion between
expert faculty and community oncologists, fostering dialogue around treatment
selection, sequencing, toxicity management, and evolving standards of care.
This collaborative format is designed to support practical, evidence-based
decision-making in everyday oncology practice.
Program Co-Chairs
Petros Grivas, MD, PhD, FASCO; Mazyar Shadman, MD, MPH
To view full profile, click on the Program Co-Chairs tab above.
